scholarly journals Cannabidiol and the Management of Pediatric Neurological Disorders: A Systematic Review

2021 ◽  
Author(s):  
Caio de Almeida Lellis ◽  
Marco Alejandro Menacho Herbas ◽  
João Cesar Pereira da Cunha ◽  
Samyla Coutinho Paniago ◽  
Paulo Sérgio Machado Diniz
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Neurological Disorders ◽  
Pediatric Patients ◽  
Meta Analysis ◽  
Dravet Syndrome ◽  
Motor Disorder ◽  
Safety And Efficacy ◽  
Catholic University ◽  
Complex Motor

Introduction: Due to an increase in cases of neurological disorders refractory to conventional treatments in pediatrics patients, other therapies have been sought. Objectives: To analyze the safety and efficacy of CBD in the management of neurological disorders in children. Design and setting: A systematic review conducted at the Pontifical Catholic University of Goiás. Methods: This is a systematic review carried out in PubMed, Lilacs and MedLine databases, with the descriptors: “(Pediatric OR Neurology) AND (Cannabidiol OR Cannabis)”, being selected only the randomized studies, meta-analysis and clinical trials published in the last 10 years. Results: One randomized trial concluded that daily oral CBD solution reduced the frequency of seizures in pediatric patients with Lennox-Gastaut syndrome (LGS). In addition, another study concluded that CBD (20 mg/kg/day) is associated with up to a 50% decrease in seizures in children with SLG and Dravet syndrome. Furthermore, it was pointed out that the association of oral CBD (2 to 5 mg/kg/day) with antiepileptic drugs caused a mean reduction of 36.5% of severe seizures. Finally, CBD enriched with 0.25% THC reduced spasticity, dystonia and pain intensity in children with complex motor disorder. Conclusion: CBD was shown to be safe and effective as a treatment for refractory epilepsies and complex motor disorder in pediatric patients, with no serious side effects reported.

Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials

2018 ◽  
Vol 56 (10) ◽  
pp. 1110-1119 ◽  
Author(s):  
Yazan Zayed ◽  
Babikir Kheiri ◽  
Momen Banifadel ◽  
Michael Hicks ◽  
Ahmed Aburahma ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Uncontrolled Asthma ◽  
Safety And Efficacy

scholarly journals Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials

BMJ Open ◽  
2020 ◽  
Vol 10 (7) ◽  
pp. e039730 ◽  
Author(s):  
Morteza Arab-Zozani ◽  
Soheil Hassanipour ◽  
Djavad Ghoddoosi-Nejad
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Code Of Ethics ◽  
Meta Analysis ◽  
Randomised Clinical Trials ◽  
Secondary Outcome ◽  
Eligibility Criteria ◽  
Safety And Efficacy ◽  
Statistical Heterogeneity

IntroductionAn outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was reported in Wuhan, China, in mid-December 2019, and declared a pandemic by the WHO on 11 March 2020. Due to the unknown nature of the disease and the lack of specific drugs, several potential treatments were used for patients. This systematic review and meta-analysis will evaluate studies of the effects of favipiravir in COVID-19 pneumonia.Methods and analysisWe will search electronic databases including LitCovid hub, PubMed, Scopus, ISI Web of Sciences, Cochrane and Embase using keywords related to COVID-19 and favipiravir. We will search the reference lists of all included studies and reviews. We will also search for clinical trial registries, such as ClinicalTrials.gov, for the ongoing clinical trials. All randomised clinical trials investigating the safety and efficacy of favipiravir compared with other control groups for the treatment of patients with confirmed infection with SARS-CoV-2 will be included. Patients’ survival at the end of the treatment as well as the follow-up will be the primary outcome of the treatment, followed by the time and rate of the patient with a negative COVID-19 test. The desired secondary outcome will consist of a decreased rate of symptoms, proportion of intensive care unit (ICU) transfers, length of the hospital stay, ICU treatments, the quality of life and additional adverse events. Data synthesis will be conducted using CMA V.2. Two independent investigators will be screening titles, abstracts and full texts of included studies, based on eligibility criteria. These investigators will then independently extract the data and appraise the quality of said studies. All potential discrepancies will be resolved through consultation with the third reviewer. Statistical heterogeneity will be assessed using a standard I2 test. A funnel plot, Egger’s test and Begg’s test will be used for detecting asymmetry to explore possible publication bias.Ethics and disseminationAll findings of this systematic review and meta-analysis will help identify the safety and efficacy of favipiravir for patients with COVID-19. Given that the design of the study is a systematic review, there is no need to follow the code of ethics protocol. The results of this study will be published in a reputable journal.PROSPERO registration numberCRD42020180032.

Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials

2018 ◽  
Vol 39 (1) ◽  
pp. 27-43 ◽  
Author(s):  
Zhihang Tao ◽  
Stanley Xiangyu Li ◽  
Kai Shen ◽  
Yunuo Zhao ◽  
Hao Zeng ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Meta Analysis ◽  
Safety And Efficacy ◽  
Efficacy Profile

scholarly journals Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis

BMJ Open ◽  
2020 ◽  
Vol 10 (3) ◽  
pp. e035080
Author(s):  
Chiara C Bortolasci ◽  
Wolfgang Marx ◽  
Adam J Walker ◽  
Kyoko Hasebe ◽  
Bianca E Kavanagh ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Neurological Disorders ◽  
Randomised Controlled Trials ◽  
Meta Analysis ◽  
Risk Of Bias ◽  
Sufficient Evidence ◽  
Controlled Trials ◽  
Controlled Clinical Trials ◽  
Randomised Controlled

IntroductionDue to the anti-inflammatory, antioxidant and anti-apoptotic properties of minocycline, clinical trials have evaluated the potential of this drug to treat several psychiatric and neurological disorders, including major depressive disorder, schizophrenia, bipolar disorder, stroke and amyotrophic lateral sclerosis. This protocol proposes a systematic review (and potential meta-analysis) that aims to identify and critically evaluate randomised controlled trials of minocycline for treating psychiatric and neurological disorders.Methods and analysisPubMed, Embase, Cochrane Central Register of Controlled Clinical Trials, PsycINFO and Cumulative Index to Nursing and Allied Health Literature (CINAHL) will be used to identify randomised controlled trials that used minocycline to treat psychiatric and neurological disorders. Double-blind, randomised, controlled, clinical trials of participants aged 18 years or older and written in English will be included in the review. Data will be extracted by two independent reviewers. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines will be followed and the Cochrane Collaboration’s ‘Risk of Bias’ tool will be used to assess the risk of bias in all studies included in the systematic review. The Grading of Recommendations, Assessment, Development and Evaluation system will be used to access the overall quality of the level of evidence of the studies. If sufficient evidence is identified, a meta-analysis will be conducted using the standardised mean difference approach and reported with 95% CIs. Heterogeneity of evidence will be evaluated using the I2model.Ethics and disseminationThis systematic review will evaluate only published data; therefore, ethical approval is not required. The systematic review will be published in a peer-reviewed journal and presented at relevant research conferences.Trial registration numberCRD42020153292.

Sign in / Sign up

Export Citation Format

Share Document